Acer Therapeutics — Opexa Therapeutics — IPO Roadshow (July 2013)
5 slides from Acer Therapeutics's IPO roadshow presentation, Jul 29, 2013
Slide 1: Issuer Free Writing Prospectus
Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-189395 July 29, 2013
Slide 2: Explanatory Note: updates to corporate presentation
EXPLANATORY NOTE: Theattachedpagesupdatethe corporatepresentationfiled asanissuerfreewriting prospectuson July22,2013: • Slide16, numberof patientsidentifiedabovethe left graphfor PercentBrainVolumeChangeat Week52: – n=32 corresponds with bar showing -0.04 percent brain volume change; and – n=18 cor
Slide 3: TERMS Study Prospective Analysis in More Active or Progressive Patients
TERMS StudyProspective - Analysis in More Active or Progressive Patients Sub-population of patients (n=50) with more progressed/active disease profile (baseline ARR >1) most closely mirrors SPMS patients Percent Brain Volume Change Change in Disability (EDSS) Annualized Relapse Rate (ARR) at Week 52
Slide 4: TERMS Study Subgroup Analysis in Patients Naïve to DMT
TERMS StudySubgroup - Analysis in Patients Naïve to DMT 1.4 73% Reduction p=0.009 1.2 1.18 1 0.8 64% Reduction p=0.046 Tcelna 0.6 56% Reduction Placebo p=0.060 0.5 0.4 0.48 0.31 0.2 0.21 0.18 0 n=53 n=28 n=45 n=25 n=16 n=8 mITT ARR > 1 ARR>1 Annualized relapse rate in DMT naïve populations. ARR in p
Slide 5: Abili-T: Landmark trial in SPMS
Abili-T: Landmark trial in SPMS • Abili-T Phase IIb clinical trial in SPMS is ongoing – Double-blind, 1:1 randomized, placebo-controlled – Inclusion criteria: Secondary Progressive MS with EDSS of 3 to 6 – 65 patients enrolled at July 19, 2013 – Immune Monitoring program conducted on a blinded basis